Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Post by DD34on Feb 05, 2018 12:14pm
71 Views
Post# 27504343

Company Tech in Laymens terms

Company Tech in Laymens terms

In layman terms, Advanced Proteome has developed a proprietary approach for streamlining the production and targeted delivery of anti-cancer drugs to cancerous tumors. The benefit is that a cancer patient’s tumor cells are destroyed selectively, sparing healthy cells.

Also of benefit is that the proprietary process we are implementing  is versatile and potentially universal in its applications to such targeted therapies. They are expected to be easier to produce and to exhibit greater potency, higher specificity and lower toxicity than current-day therapies that do destroy a cancer patient’s normal healthy cells.

Targeted therapies, such as Advanced Proteome’s approach, home in on cancer cells thereby avoiding the nasty side effects of traditional chemotherapeutics.

Advanced Proteome’s approach, in addition, exploits universal features of antibodies, thereby simplifying and standardizing, as well as accelerating the process of creating new antibody-drug conjugates.

Because of the benefits of our innovative approach over traditional approaches, we expect to profoundly impact  the markets for anti-cancer therapeutics.

Bullboard Posts